INTRODUCTION
Granulopoiesis is a complex process closely regulated by several transcription factors and cytokines. 1, 2 The identification of the promyelocytic leukemia/retinoic acid receptor α (PML-RARα) fusion protein as the founding abnormality initiating a differentiation blockage at the origin of acute promyelocytic leukemia (APL) allowed to identify the central role of RARα in the regulation of granulopoiesis. 3, 4 Indeed, the PML-RARα protein resulting from the reciprocal t(15;17) translocation impedes the expression of RARα target genes through abnormal binding to corepressor proteins. 5, 6 This transcriptional block leads to a differentiation block of the APL leukemic cells at the promyelocytic stage. RA, the natural ligand of RARα, is a well-known inducer of terminal differentiation of APL cells, and PML-RARα degradation 7 that, when associated with chemotherapy or arsenic trioxide (ATO), which equally degrades PML-RAR 8 leads to highly efficient treatment of this disease. 9, 10 However, a percentage of patients still relapse because of the emergence of RA-resistant cell clones. Such clones have been described to harbor mutations in the ligand-binding domain of PML-RARα. 11, 12 Furthermore, we have identified that epigenetic modifications of the RARα promoter may equally be involved in the absence of RA target gene expression. Restoration of the RARα promoter permissiveness and leukemic differentiation was achieved by activating the MEK/ERK signaling pathway through granulocyte-colony-stimulating factor (G-CSF) receptor activation. 13 In other cell types, the regulation by posttranslational modification of nuclear receptors after intracellular signaling activation has been well described. 14 More precisely, the MEK/ ERK pathway is involved in the regulation of many nuclear receptor functions. 15 In the case of RA receptors, a cross-talk between kinase cascades and genomic pathways has been well established, 5 which could lead to novel approaches in the development of anticancer therapies. 13 In this study, we sought whether activation of the MEK/ERK intracellular pathway in APL cells by molecules other than G-CSF and its receptor would enhance differentiation in RA-resistant APL cells. The results lead to the selection of glycogen synthase kinase-3β (GSK-3β) inhibitors, among which lithium chloride (LiCl) was identified as a potential candidate to test for preclinical models, as already administered to patients as a mood modulator.
GSK-3β is a ubiquitously expressed serine-threonine kinase with a large number of intracellular targets. This enzyme has been implicated in glycogen metabolism and several physiological processes such as proliferation, survival and stem cell maintenance. 16, 17 In hematopoietic stem cells (HSCs), GSK-3β has been shown to regulate the choice between self-renewal and differentiation, 18, 19 whereas mice treated by GSK-3β inhibitors showed an increase in the repopulating capacity of HSC. 18 GSK-3β inhibitors have been developed for the treatment of neurological disorders such as Alzheimer's disease, and LiCl is used as a mood modulator. GSK-3β inhibitors have been reported to have potent antileukemic activity in mixed-lineage leukemia (MLL)-associated leukemia. 20 Furthermore, antileukemic effects of GSK-3β inhibition on acute myeloid leukemia (AML) and RA-sensitive APL cells have also been reported. 21, 22 In the present study, we show the efficacy of LiCl and GSK-3β inhibitors in RA-sensitive APL in both in vitro and in vivo models and highlight for the first time that these drugs can potentiate RA efficacy in RA-resistant APL cells. The mechanisms underlying this efficacy are shown to be mediated through the activation of the MEK/ERK pathway.
MATERIALS AND METHODS Cells
Mononuclear cells from patient's bone marrow samples at diagnosis were prepared by Ficoll-Hypaque density gradient purification, and the presence of the PML-RARα fusion was verified by reverse transcription-PCR as described previously. 23 The UF-1 cell line was obtained from Dr Ikeda (Tokyo, Japan) and cultured in RPMI supplemented with 15% stromal vascular fraction at 37°C in a humidified atmosphere containing 5% CO 2 . NB4 cells were cultured in RPMI supplemented with 10% SVF at 37°C in a humidified atmosphere containing 5% CO 2 .
Reagents
LiCl was obtained from Sigma Chemicals (Saint-Quentin Fallavier, France) and diluted in water. For in vitro experiments, the concentration used was 25 mM, except where indicated. The MEK/ERK inhibitor UO126 was purchased from Calbiochem (San Diego, CA, USA). Four different GSK-3β inhibitors were obtained from Targeon SAS (Paris, France), namely, TGO151 (half-maximal inhibitory concentration (IC 50 ): 64 nM), TGO262 (IC 50 :9 nM), TGO212 (IC 50 : 24 nM) and TGO371 (IC 50 : 56 nM). These molecules were tested in vitro and demonstrated as selective GSK-3β inhibitors and able to induce Tau phosphorylation. Every molecule was used at 3 μM, with the exception of TGO262, which was used at 10 μM. Antibodies against ERK1/2, phospho-ERK1/2, GSK-3β and phospho-GSK-3β (serine 9) were purchased from Cell Signalling (Leiden, The Netherlands), phycoerythrin-labeled antibody against CD11b was from Pharmingen (Le Pont de Claix, France) and Alexa Fluor 405-labeled anti-PML was from Santa Cruz (Dallas, TX, USA). The small interfering RNAs directed toward MEK1 and MEK2 were purchased from Qiagen (Hilden, Germany; FlexiTube gene solution; GS5594 and GS5595).
Differentiation of APL cells
The sensitivity of cell lines and patient cells to RA-induced differentiation was assessed by the appearance of burst function (nitroblue tetrazolium test) as described previously 24 and by FACS analysis of CD11b surface expression using a FACSCalibur apparatus (Becton Dickinson, Le Pont de Claix, France). Transactivation UF-1 cells were electroporated as described previously 13 with luciferase reporter genes hRAR2-Luc or RARE3-TK-Luc (5 μg) and treated or not with all-trans RA (ATRA) and/or G-CSF. All transfections were performed with a galactosidase expression vector (pCH110) as an internal standard. Twentyfour hours after transfection, the luciferase activity was determined according to a standard procedure. Results were expressed as fold induction based on the basal activity of the reporter gene (arbitrarily set at 1) in the absence of any ligand.
Cell extracts and immunoblotting
Cells were lysed in 20 mM Tris, pH 7.4, 150 mM NaCl, 10 mM EDTA, 10% glycerol, 1% Igepal, 1 mM orthovanadate and Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland). Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After electrotransfer, antigen-antibody complexes were revealed by means of peroxidaselabeled secondary antibodies and an enhanced fluoro-chemiluminescence system (ECL Plus Amersham Biosciences, Velizy-Villacoublay, France).
Quantitative reverse transcription-PCR
Total RNA was extracted using Trizol reagent according to the manufacturer's instructions. RARα2 gene expression was analyzed as described 13 and normalization was obtained with ABL gene expression. Results were expressed using the ΔΔCt method.
Animal model
Procedures involving animals and their care conformed to institutional guidelines, which comply with national and international laws and policies and were authorized by the local ethics committee. Transgenic mice bearing the human PML-RARα cDNA (bcr1) were previously constructed in FVB/N inbred strain of mice and a transplantable model was established in which 100% of the mice die of the disease. 25 To allow reproducible APL development, we injected intravenously 10 4 APL spleen blast cells into 8to 10-week-old syngeneic recipients (FVB/N mice bred and maintained under pathogen-free conditions in the Départment d'Expérimentation animale, Institut Universitaire d'Hématologie, Université Paris-Diderot). Establishment and follow-up of leukemia was assessed by the appearance of high leukocyte and low platelet counts. We administered RA by subcutaneous implantation of 21-day release pellets containing 5 mg of ATRA (Innovative Research of America, Saratosa, FL, USA) as described previously. 26 APL blasts were injected on day 0, a week later ATRA pellets were introduced subcutaneously and the following day LiCl at a dose 0.18 g/100 ml was dissolved in drinking water and supplied ad libitum. Lithium concentration was determined in the serum by Flame Atomic Emission Spectrometry on an IL 943 photometer (Instrument Laboratory, Le Pré Saint Gervais, France) using Cesium as the internal standard. Mice were kept under observation until spontaneous death. Control animals received tap water.
RESULTS

LiCl modulates MEK/ERK and GSK-3β pathways
The UF-1 cell line has been isolated from an APL patient at relapse after RA treatment and was shown to harbor the recurrent mutation R276W of the RARα ligand-binding domain in the PML-RARα fusion gene, 11 thus representing a potent model of RA resistance. We previously observed 13 that the cotreatment of this cell line with RA and G-CSF restored the differentiation in an MEK/ ERK-dependent manner. We demonstrated that this pathway was able to restore RA target gene promoter permissiveness. 13 To further study the activation of the MEK/ERK-dependent differentiation as a mean to overcome RA resistance, various compounds were screened for their capacity to activate the mitogen-activated protein kinase pathway. LiCl was found to be a rapid inducer of ERK1/2 phosphorylation. Indeed, a significant increase in the phosphorylation was observed within 15 min compared with RA alone (Figure 1a ). We used LiCl at the concentration of 25 mM, a commonly used concentration for in vitro studies. When combined with RA, LiCl was still able to significantly increase ERK1/2 phosphorylation. Similarly, 15mM of LiCl treatment of fresh APL patient blasts at diagnosis were sufficient to increase ERK1/2 phosphorylation significantly. Finally, because the preincubation of both UF-1 and APL patient cells with Lithium chloride antileukemic activity in APL the well-known MEK inhibitor UO126 completely abolished this phosphorylation (Figure 1a ), we concluded that LiCl was able to activate the MEK/ERK pathway in a manner similar to G-CSF, as we have reported in these cells. 13 Lithium is a well-known mood modulator, acting through the inhibition of the GSK-3β kinase by stabilizing the phosphorylation of serine 9. 27 As shown in Figure 1b , G-CSF as well as LiCl triggers the phosphorylation of GSK-3β on serine 9 within 1 h. Of note, levels of phosphorylation were not modified when RA was combined with LiCl.
LiCl has antiproliferative and proapoptotic effects in RA-sensitive APL cells Because both MEK/ERK and GSK-3β pathways are involved in the regulation of cell cycle and apoptosis, we first analyzed the effects of LiCl treatment on proliferation and survival in the RA-sensitive (NB4) cells. The proliferation rate of NB4 cells was assessed during culture in the presence of LiCl alone or combined with RA. As shown in Figure 2a , in the presence of LiCl, an arrest of cell growth was noted as from day 1. RA at two different concentrations had little effect on cell proliferation and viability and did not counteract the antiproliferative effect of LiCl (Figure 2a ). We then evaluated whether LiCl could induce apoptosis in APL cells. An important increase in apoptotic cells beginning on day 1 of culture was observed (31% of Annexin V-positive/propidium iodide-negative cells compared with 16% in untreated cells) (Figure 2b ). RA by itself did not induce apoptosis in NB4 cells as already reported, 28 and RA did not antagonize the proapoptotic effect of LiCl (Figure 2c ). LiCl-induced apoptosis was shown to be caspase-dependent as caspase-3 cleavage was observed after 48 h with LiCl alone or LiCl+RA (Figure 2d ). Corroborating the absence of RA-induced apoptosis, no caspase-3 cleavage was observed in NB4 cells treated with RA alone. The proapoptotic effect of LiCl on NB4 cells was observed in a dose-dependent manner. Indeed, the percentage of apoptotic cells augmented with increasing LiCl doses from 5 to 25 mM ( Figure 2f ).
As proof of concept of possible LiCl clinical efficacy, we took advantage of a well-characterized transplantable preclinical mouse model of APL that mimics the human disease both in its biological characteristics and its response to conventional therapeutics such as ATRA and ATO. 26, 29 In this model, transplantation of APL spleen blast cells into syngeneic recipients induces a fatal leukemia within 40 days with a 100% penetrance as shown in Figure 3b . LiCl was added in the drinking water at a dose of 0.18 g/ 100 ml, which allowed to obtain reproducible LiCl plasma levels among mice (median: 0.76 ± 0.28 mmol/l) ( Figure 3a) . These levels were similar to the therapeutic concentrations expected in humans of 0.7-1.2 mmol/l). ATRA was administered subcutaneously as suboptimal dose (5 mg) pellets to allow the observation of a beneficial effect of the combination. In our preclinical trial (Figure 3b ), 32 leukemic mice were separated into four therapeutic groups: untreated, treated with ATRA only, with LiCl only and with ATRA combined to LiCl. Mice treated with ATRA (a reference treatment) had a significantly (Po 0.0001) extended survival compared with the untreated group. Interestingly, mice treated with LiCl alone had a similar survival compared with mice treated with ATRA, strongly indicating the antileukemic effect of LiCl. When ATRA and LiCl were combined, a further increase in survival was observed compared with drugs given alone (P = 0.0003). Taken together, these results show that treatment with LiCl (alone or combined to ATRA) provides a significant survival advantage in APL leukemic mice.
LiCl and GSK-3β inhibitors restore RA-induced differentiation in RA-resistant APL cells The antiproliferative effect of LiCl alone or when combined to RA was tested in the UF-1 RA-resistant cells. We noted a significant reduction of the number of viable cells after 2 and 5 days of culture, confirming the antiproliferative effect of LiCl (Figure 2e ). Interestingly, although LiCl given alone induced apoptosis in UF-1 cells to an extent similar to that observed in NB4 cells, addition of RA to UF-1 cells protected against LiCl-induced apoptosis, a phenomenon not observed with the NB4 cells ( Figure 2f ). We next asked whether the antiproliferative and proapoptotic effects of GSK-3β inhibitors could be related to a differentiating effect on leukemic cells. We monitored differentiation induction by the expression of the differentiation marker CD11b and the functional oxydo-reduction-based nitroblue tetrazolium test. As expected, LiCl or RA alone were not able to induce the differentiation of UF-1 cells (Figures 4a and b) . However, the combination of both drugs induced terminal differentiation of UF-1 cells to levels reached in the RA-sensitive NB4 cell line with RA alone at 10 − 7 M (Figure 4a ). When combined to RA, LiCl increased the differentiation of UF-1 cells in a dose-dependent manner (Figure 4b ). Indeed, starting from 5 mM LiCl that had no effect, we observed an increase in CD11b-positive cells of 33% with 10 mM and 100% with 25 mM LiCl. Of note, the treatment by NaCl 25 mM had no effect, excluding a potential 'salt effect' of LiCl treatment (Figures 4a and b) . These data were corroborated in primary APL cells where the combination RA+LiCl for 3 days increased the percentage of CD11bpositive cells compared with treatment by RA alone (Figure 4c ). We next tested four different GSK-3β inhibitors for their potential effect on UF-1 cell differentiation. Although none was able to modulate differentiation by itself (data not shown), each of these drugs, combined with RA, restored the differentiation of UF-1 cells after 3 or 6 days ( Figure 4d ). Bearing in mind our recent results involving the ERK1/2 mitogen-activated protein kinase pathway in the potentiation of RA-induced differentiation of RA-resistant cells, 13 we analyzed the impact of inactivating this pathway on the effect of GSK-3β inhibitors. The pretreatment of UF-1 cells or APL patient cells by UO126, an MEK/ERK1/2 inhibitor, fully abolished the differentiation induced by the combination of RA and LiCl or a GSK-3β inhibitor. Indeed, the percentages of CD11b-positive cells were similar in cells treated by RA alone or treated by the combination+UO126 (Figures 4e and f) . Thus, the restoration of RA sensitivity in both UF-1 cell line and patient cells by LiCl was mediated through the MEK/ERK pathway. This was further confirmed using an RNA interference approach with small interfering RNA directed towards MEK1/2, which abrogated the activation of ERK1/2 (not shown) and significantly reduced the RA +LiCl-induced differentiation (Figure 4g ).
LiCl induces PML-RARα degradation and restores the RA transcriptional activation of target genes
One main effect of RA at pharmacological doses in APL cells is to restore the activation of RA target genes, including the RARα gene, mainly the RARα2 isoform 30 and to induce PML-RARα degradation. 7 As reported previously 13 and shown in Figure 5a , RARα2 is expressed at low levels in UF-1 cells even after treatment with RA, confirming the RA resistance of these cells. When LiCl was combined with RA, the expression of the RARα2 isoform was induced in a dose-dependent manner (Figure 5a ), whereas the PML-RARα protein was degraded (Figure 5b ) and nuclear bodies reorganized (Supplementary Figure S1 ). Increased upregulation of RARα2 was further confirmed in APL patient's leukemic cells after treatment with RA combined with LiCl (Figure 5c ). Finally, the combination of RA with a GSK-3β inhibitor was also synergic on Lithium chloride antileukemic activity in APL RARα2 expression (Figure 5a ). Using a plasmid construct in which an RA-responsive element (RARE) was cloned upstream of the luciferase gene, we confirmed that LiCl restores RA-dependent transcription, which is impaired in UF-1 cells (Figure 5d ). Finally, inhibition of the MEK/ERK1/2 pathway abrogated the transcriptional activation induced by the RA+LiCl combination. Indeed, when the cells were pretreated with UO126, the transcriptional activity fell back to the level observed with RA alone in both the RARα2 expression ( Figure 5a ) and the luciferase activity from a RARE cosntruct (Figure 5d ). These results highlight the major role of the MEK/ERK1/2 activation downstream of LiCl and other GSK-3β inhibitors in the regulation of the RA-dependent transcription activity in APL-resistant cells.
DISCUSSION
In our attempts to identify molecular pathways able to increase RA-induced differentiation, we recently identified the G-CSF-activated MEK/ERK1/2 mitogen-activated protein kinase pathway. 13 In the present study, we report on the antileukemic potential of GSK-3β inhibitors and LiCl in RA-sensitive and -resistant APL cells, in vitro and in vivo. The GSK-3β enzyme is a constitutively active serine-threonine kinase known to be involved in several physiological processes by regulating intracellular signaling pathways, among which the Wnt/β-catenin and the PI3K/AKT/mTORC1 pathways are the most studied. 17 GSK-3β is inactivated after phosphorylation at serine 9 residue by AKT in response to various growth factors. 31 In this study, we demonstrated that the GSK-3β enzyme is also involved in the regulation of the mitogen-activated protein kinase pathway as several GSK-3β inhibitors induced a rapid phosphorylation of ERK1/2. This phosphorylation was dependent on MEK activation as under MEK inhibition we observed the abrogation of ERK1/2 phosphorylation induction. The mechanisms leading to MEK activation after GSK-3 inhibition are not fully elucidated but several clues from the literature may help to understand. The involvement of the ERK1/2 pathway in GSK-3β inhibitor-induced biological activities has already been suggested in other models. Activity of lithium in hippocampal cells was linked to the upregulation of ERK1/2 phosphorylation and counteracted by UO126 (an MEK inhibitor). 32 It was also shown that lithium participates in increasing MEK activity in neurons. 33 In another study, lithium-induced neuronal differentiation was ERK-dependent. 34 The molecular mechanisms involved in ERK1/2 phosphorylation after lithium treatment were not clear in these studies and have been suggested to be secondary to the induction of growth factor secretion that would then activate the Ras/MEK/ERK pathway through growth factor tyrosine kinase receptor. In our study, the upregulation of ERK1/2 phosphorylation was very rapid suggesting a direct effect on signaling molecules. In monocytes, GSK-3 was reported to negatively regulate the ERK1/2 phosphorylation through the activation of the inhibitory kinase Rac1. In these cells, GSK-3β inhibition using diverse inhibitors including lithium upregulated the phosphorylation of ERK1/2 induced by lipopolysaccharides. 35 Although in this model GSK-3β inhibition only increased the level of an already phosphorylated ERK1/2, in our model lithium treatment induced ERK phosphorylation. Thus, the mechanism through which GSK-3 inhibition can induce ERK1/2 phosphorylation is most certainly cell context-dependent.
In normal hematopoiesis, the GSK-3 enzyme has a role in the regulation of HSC homeostasis and particularly in the regulation of the decision between self-renewal or lineage commitment, 19 notably through the regulation of the Wnt/β-catenin pathway in HSC. 36 In cancer, the GSK-3 enzyme has been suggested as an interesting therapeutic target. 37 Indeed, GSK-3 has many effects on cell growth by regulating cell cycle effectors such as p21 CIP1(ref.38) or the cyclin-cdk complex Clb2-Cdk1. 39 In chronic myeloid leukemia, for example, an abnormal splicing inducing a deletion in the GSK-3β has been involved in blast crisis development and leukemic stem cells development. 40 Although the role of GSK-3β in leukemogenesis has been suggested but not clearly explained, the therapeutic potential of GSK-3β inhibitors in AML treatment has already been suggested in several studies. Using a screen based on AML cell line differentiation, Banerji et al. 41 have identified lithium and other GSK-3β inhibitors as possible antileukemic agents, but the mechanism was not identified. A more targeted effect of GSK-3β inhibition was shown in MLL-rearranged subtype of AML. 20 In this study, GSK-3 was shown to be required for the maintenance of MLL leukemias as both inhibition of GSK-3 enzymatic activity or expression resulted in an antileukemic activity in several models. The mechanisms reported involved both the suppression of the cyclin-dependent kinase inhibitor p27 Kip1 expression 20 and the regulation of critical gene expression responsible for the MLL oncogenic program. 42 Thus, GSK-3 appears to be involved in tumorigenesis through the regulation of specific oncogenic pathways such as MLL in leukemia. In our study, we report on another selective activity of GSK-3β in APL. Indeed, we observed that GSK-3β inhibitors either alone or in combination with RA have antileukemic activities. In previous studies, 21, 22, 43 GSK-3 inhibitors have been reported to be able to regulate the differentiation of this particular subtype of leukemia, although the mechanisms were not clearly explicated. The first reports were made on the synergistic action of ATRA with LiCl on the differentiation of AML and APL blast cells. 43 More Lithium chloride antileukemic activity in APL recently, two different studies reported that GSK-3β inhibitors may increase the differentiation of APL cells when combined to RA. 21, 22 In these studies, performed on RA-sensitive APL cell lines, GSK-3β was shown to antagonize the transcriptional activity of RARα and to directly phosphorylate the RARα protein. However, how this mechanism participated in the differentiation effect of RA in APL cells harboring the PML-RARα fusion protein remains unclear. In our study, we identified GSK-3β inhibitors as powerful agents to induce the differentiation of RA-resistant cells in which the RAresponsive promoters were unresponsive to RA, because of a mutation in the ligand binding of PML-RARα. Although the cure rate of APL patients in most countries is now very high, 9, 10 it is known that maximal response to RA differentiation is an important factor to prevent relapses. We have previously shown that activation of the MEK/ERK1/2 pathway could release the unresponsiveness of RA-responsive promoters in APL cells 13 and restore differentiation of RA-resistant APL cell lines and patient leukemia cells. Through a chemical screen aiming at selecting agents that could induce rapid phosphorylation of ERK1/2, we identified GSK-3β inhibitors. Using several GSK-3β inhibitors including LiCl, we confirmed that the MEK/ERK1/2 pathway activation could contribute to restore RA-induced differentiation of RA-resistant APL cells. We also demonstrated that RA-induced transcriptional activation of target genes was restored in correlation with the degradation of the PML-RARα protein. Taking advantage of the well-established APL animal model, 26 we tested for a preclinical application of LiCl and observed a marked increase in the survival of mice treated by the combination of RA and LiCl. We thus demonstrated in vivo the synergistic action of LiCl combined with RA, confirming the benefit of increasing differentiation of APL cells. Furthermore, and more unexpectedly, we observed that LiCl by itself had an antileukemic activity in this model. Indeed, the lifetime expectancy of mice treated by LiCl alone was increased to an extent similar to that observed in RAtreated mice. This result may be explained by the antiproliferative and proapoptotic effects we and others 44 observed in APL cells treated with LiCl alone in vitro. Finally, based on results published by Wang et al. 45 reporting on a positive effect of GSK-3β on the proapoptotic effects of ATO, it would be expected that combining a GSK-3β inhibitor such as LiCl with ATO alone may have antagonistic potential. However, because ATO used at low doses is also able to induce differentiation, further investigations may be useful to analyze carefully the combination of LiCl and ATO in APL cell differentiation.
In summary, our findings confirm the importance of activating the MEK/ERK1/2 pathway in avoiding RA resistance in APL. We further demonstrate the clinically relevant potential of GSK-3 inhibitors as antileukemic agents and extend the field of application of such agents. Indeed, although APL patients benefit nowadays from highly efficacious and well-tolerated treatments, 22 some patients experience multiple relapses because of resistance. More importantly, relative but insufficient sensitivity to RA have been reported in AML other than APL. The combined approach described herein could deserve further investigations in those patient subsets.
